Deciphera Pharmaceuticals Inc $ 48.4 -0.13 (-0.27%)
Volume:
584,146
Avg Vol (1m):
500,895
Market Cap $:
2.70 Bil
Enterprise Value $:
2.03 Bil
P/E (TTM):
0.00
P/B:
4.02
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 40.45 | ||
| Equity-to-Asset | 0.92 | ||
| Debt-to-Equity | 0.03 | ||
| Debt-to-EBITDA | -0.08 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 25.87 | ||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -905.61 | ||
| Net Margin % | -868.56 | ||
| ROE % | -47.59 | ||
| ROA % | -42.94 | ||
| ROC (Joel Greenblatt) % | -1677.78 | ||
| 3-Year EBITDA Growth Rate | -53.6 | ||
| 3-Year EPS without NRI Growth Rate | -45.6 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 4.02 | ||
| PS Ratio | 73.87 | ||
| EV-to-EBIT | -9.33 | ||
| EV-to-EBITDA | -9.38 | ||
| EV-to-Revenue | 80.97 | ||
| Current Ratio | 15.61 | ||
| Quick Ratio | 15.61 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -35.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.01 | ||
| Earnings Yield (Greenblatt) % | -10.72 |